Presenter: Anthony H Barnett, MB BS, MD, University of Birmingham and Birmingham Heartlands Hospital (Birmingham, UK) The first long-term study to compare an angiotensin receptor blocker (ARB) and an ...
Telmisartan (Micardis, Boehringer Ingelheim), a nonpeptide AT-II-receptor antagonist, gained FDA approval for use in the treatment of hypertension in 1998. After oral administration, peak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results